HIF-1α Stabilization As a Novel Therapeutical Approach for Sarcopenia.
Recruiting
N/A
Interventional Study
Sarcopenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 65 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 105 (estimated)
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Age-related sarcopenia is associated with reduced mobility, functional decline and disability, falls, and mortality in the elderly. Loss of skeletal muscle is the focus of the disease and is the result of progressive atrophy and loss of glycolytic-type muscle fibers. Muscle mass declines at a rate of 3-5% per decade after thirty years, and the decrease accelerates further after sixty years (Patel …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* For non-sarcopenic patients aged 18 to 35 years, for sarcopenic patients aged \> 65 years.
* 18 ≤ body mass index (BMI) ≤ 30 kg/m2.
* For the sarcopenic group:
1. non-inflammatory degenerative joint disease, including osteoarthritis and outcomes of congenital hip dysplasia.…
Contacts